A new class of “encrypted RNA” vaccines are being developed where the RNA would piggyback onto an existing wild virus and spread from person to person without any person’s knowledge or consent. Although this may sound like science fiction, it is far from it. Two companies involved in this research have received millions of dollars from the federal government. A study using this technology on hamsters and the SARS-Cov-2 virus has already been completed and a Phase I trial on humans is in the works. ICAN’s attorneys have already sent legal demands to all government agencies involved.
It seems the government and the military are so enthused about this new vaccine deployment technology that Congress tucked a law, the PREVENT Pandemics Act, into the 2023 omnibus appropriations bill to facilitate it. Among other things, the Act has a section dedicated to Platform Technologies that supports the “development and review of new treatments and countermeasures that use cutting-edge, adaptable platform technologies that can be incorporated or used in more than one drug or biological product.”
This Act will also be used to fund a new HHS government agency called ARPA-H (Advanced Research Projects Agency for Health), which was created in 2023 to “take big technical risks that can spark new biomedical breakthroughs” and “revolutionize the detections, diagnosis, mitigation, prevention, treatment and cure of diseases and health conditions.” Both former NIH Director Francis Collins and HHS Secretary Xavier Becerra supported the agency’s creation, and Collins described his vision for ARPA-H as “a DARPA-like culture at NIH.”
This so-called “therapy” uses a technology called TIPs (Therapeutic Interfering Particles), which are described as “engineered molecular parasites” that piggyback on a wild virus. If you get the virus, you also get these parasites. Once inside an infected person, the TIPs are supposed to rapidly multiply, hijacking the resources the wild virus needs to multiply and therefore stopping the virus.
Supporters of this technology claim it will “solve” several problems with traditional vaccine delivery, including “behavior barriers” like noncompliance. Meaning everyone gets vaccinated—whether they like it or not.
One of the companies developing this technology is Autonomous Therapeutics, led by Dr. Ariel Weinberger. Autonomous has received over $15 million in federal government contracts and grants, including an ongoing $4.58 million award from DARPA (a Department of Defense agency) for “A Rapid-Response Platform to Develop & Deliver TIPs Against Respiratory Viral Threats, Including MERS-CoV” and a $3 million contract from DARPA for “New Platform Technologies for Viral and Therapeutic Evolution Assays” that was completed in 2022. Dr. Timothy Notton is the Chief Scientific Officer at Autonomous and his bio references his work on “automated screening platforms (inhalable) LNP delivery platforms.”
In a recent article, Ariel gushes:
This next-generation RNA, which we aim to advance at Autonomous Therapeutics Inc., is designed to encode an artificial immune system that can detect and eliminate every variant of a viral family. We have developed encrypted RNA candidates with potential variant-proof efficacy against a wide range of pathogens, from coronaviruses to influenza and RSV. These can be made inhalable and shielded from human immune systems to enable safe and long-term prophylaxis. (Emphasis added.)
The other company working on similar vaccines, VxBiosciences, appears to collaborate with the J. David Gladstone Institutes, led by Dr. Leor Weinberger—who happens to be Ariel’s brother. Patents are already established, such as this one by Leor and Gladstone Institutes in 2017. In a 2020 TEDMED talk, Leor talked about how using viruses would “convert super-spreaders from spreading the virus to spreading the therapy.”
HHS issued a $4.8 million grant to VxBiosciences for “Autonomously Deploying, Co-evolving SARS-CoV-2 Antiviral.” The grant was for engineering “therapeutic molecular parasites of SARS-CoV-2 that can co-adapt and transmit among infected hosts … acting as single-administration therapies that circumvent compliance issues.”
So, how safe are these “inhalable therapies”? What could possibly go wrong with a man-made parasite designed to self-replicate in your cells and to transmit without anyone’s knowledge or consent? Your guess is as good as ours. But we’d prefer not to find out.
Through its attorneys, ICAN has already submitted numerous FOIA requests to DARPA, DOI, the Navy, and NIH concerning these grants and contracts to ascertain the truth about who stands to benefit from these alarming products.
ICAN is already deploying a legal strategy to ensure that individuals will never be infected with engineered viruses and bacteria without their express consent.
ICAN is also keeping a close eye on a new COVID-19 nasal vaccine, called CoviLiv, developed by Codagenix. It is described as “designed using the Codagenix platform technology that re-codes the genetic material of a virus – converting the virus from a disease-causing pathogen into a stable and safe, live-attenuated vaccine.” No word yet on whether they anticipate this vaccine could spread from person-to-person, but they have just received funding from the Biomedical Advanced Research and Development Authority (BARDA).
Stay tuned for more on this issue as ICAN has instructed its legal team to dig further into these types of developing technologies that would permit involuntary, widespread delivery of pathogens that result in a complete and permanent revamping of our God-given immune systems without requiring any informed consent. ICAN has also, as noted, instructed its legal team to deploy a well-crafted strategy intended to ensure these technologies cannot be used to infect anyone without their consent, and it hopes to bring good news in the near future about that strategy.
See below for some of ICAN’s other letters demanding answers from federal agencies:
